TLR4 and Sepsis: Additionally, specific risks exist for different targets; for instance, systemic TLR4 agonists may induce sepsis-like reactions, while TLR7/8/9 agonists require attention to their potential risk of inducing autoimmune-like symptoms (Hug et al., 2020; Del Prete et al., 2019).